ResearcherNorthwestern UniversityActive in the last 2 years
Karl A. Scheidt
Matched on ORCID iD 0000-0003-4856-3569; OpenAlex author ID A5041041100. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 5
2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 2
- Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. Last author DOI 10.1021/acschembio.6c00580↗
- Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma. Last author DOI 10.1021/acsmedchemlett.1c00376↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Thao D. Pham · 2 shared papers, 2021–2026 · strength 0.49
- Paper Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. DOI 10.1021/acschembio.6c00580↗
- Paper Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma. DOI 10.1021/acsmedchemlett.1c00376↗
- Hidayatullah G. Munshi · 2 shared papers, 2021–2026 · strength 0.49
- Paper Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. DOI 10.1021/acschembio.6c00580↗
- Paper Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma. DOI 10.1021/acsmedchemlett.1c00376↗
- Gina M. Connors · 1 shared paper, 2026 · strength 0.32
- Jeffrey H. Becker · 1 shared paper, 2026 · strength 0.32
- Ada Jade Kwong · 1 shared paper, 2021 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.